-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Compilenewborn
On April 12, Merck (Merck KGaA) announced the key clinical progress of berzosertib (M6620).
The results of a phase II proof-of-concept study (NCT02487095) conducted by the National Cancer Institute (NCI) showed that in patients with recurrent small cell lung cancer (SCLC), berzosertib combined with the chemotherapy drug topotecan is objective The response rate (ORR) was 36% (95% CI: 18.
NCI is also conducting a separate phase II trial to evaluate berzosertib combined with topotecan and topotecan monotherapy in the treatment of recurrent SCLC (NCT03896503).
Merck also initiated a global phase II study to further evaluate the efficacy of berzosertib combined with topotecan in the treatment of relapsed platinum-resistant SCLC (DDRiver SCLC 250).
Topotecan is the standard of care chemotherapy for the second-line treatment of SCLC and is associated with low remission rates, especially in platinum-resistant diseases.
These results are in addition to the results of an open-label, randomized, phase II study (NCI protocol 9944) sponsored by NCI, which evaluated the efficacy of berzosertib combined with gemcitabine and gemcitabine in the treatment of relapsed, platinum-resistant high-grade serous ovarian cancer.
Reference source: Merck Advances ATR Inhibitor Berzosertib in Small Cell Lung Cancer With New Published Data and Initiation of Phase II Trial With Registrational Intent
